Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
JUNS
JUNS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
JUNS News
Jupiter Launches Nugevia™ to Support GLP-1 Weight Loss
Jan 28 2026
Newsfilter
Jupiter Neurosciences to Attend DealFlow Conference
Jan 28 2026
NASDAQ.COM
Jupiter Neurosciences to Host Investor Webinar on January 6, 2026
Dec 23 2025
Globenewswire
Jupiter Neurosciences Advances JOTROL™ into Phase 2a Parkinson's Trial and Launches Nugevia™ Brand
Dec 03 2025
Newsfilter
Daily Update on VTI ETF – November 24, 2025
Nov 24 2025
TipRanks
VTI ETF Daily Report — November 21, 2025
Nov 21 2025
TipRanks
VTI ETF Daily Update - November 20, 2025
Nov 20 2025
TipRanks
Daily Update on VTI ETF – November 18, 2025
Nov 19 2025
TipRanks
Jupiter Neurosciences Obtains FDA Approval for IND Application to Start Phase 2a Clinical Trial of JOTROL™ for Parkinson's Disease
Nov 05 2025
Newsfilter
Jupiter Neurosciences Appoints Innovative Entrepreneur and Biohacker Jean Fallacara as the Third Ambassador for Nugevia™ Brand
Sep 15 2025
Newsfilter
Jupiter Neurosciences Introduces Nugevia™ MND: A Cognitive Health Supplement Leveraging Clinically Validated Neuroscience
Aug 11 2025
Newsfilter
Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery
Jun 30 2025
Yahoo Finance
Jupiter Neurosciences Unveils Nugevia™ GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science
Jun 27 2025
Newsfilter
Why Oracle Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Jun 12 2025
Benzinga
Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter
Apr 08 2025
Newsfilter
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 06 2025
Business Insider
Show More News
